U.S. imperialism's Chief Executive Officer a.k.a. President O' Bummer will be visiting India soon and is likely to bring pressure to bear on India with regards patents on pharmaceuticals on behalf of the big U.S. pharmaceuticals giants.
Hopefully, India's President Narenda Modi will tell President O' Bummer to shove it but let us too stand up independently for India's poor and sign this petition below.
la Luccha Final
===============================
President Obama will fly to India in days. Right now he’s hearing most from the Big Pharma lobby, so let’s race to hit our one million target and stand strong for affordable medicine around the world.
Now help boost our call by sending the email below to friends and family, and share this link on Facebook:
Thanks for all that you do,
The Avaaz team
PS - Many Avaaz campaigns are started by members of our community! Start yours now and win on any issue - local, national or global: http://www.avaaz.org/en/petition/start_a_petition/
-----------
Dear friends,
President Obama’s visit to India in days could spell life or death for millions of poor people in Asia, Africa and Latin America, but if we move fast we can ensure they can still get the medicines they need.
India produces cheap HIV, malaria and cancer drugs, but Big Pharma wants to stop this, to sell their own products at higher prices. Their fierce lobby has got the US to push their line hard, even threatening trade sanctions if India doesn’t change patent laws which put people before profits. Now pressure is rising with talks set to begin on an investment treaty.
Before Obama flies, let’s build a million-strong call to protect India’s proud role as the pharmacy to the world’s poor, make it a mega media story while he is there and then deliver it with our own common sense trade plan developed by experts that protects access to medicine. Add your name now:
Pharma giants say India’s patent laws allow companies to undercut them, deterring them from investing in new medicines. But drug companies prioritise researching drugs for the rich, not the poor, and they often price their products sky high -- a new hepatitis C treatment currently sells for $1000 per pill!
At a White House breakfast last October, India's Prime Minister Narendra Modi told Big Pharma CEOs to invest in affordable medicines, rather than play legal games to squeeze every drop from their existing patents. But he agreed to set up an Indo-US forum on drug patent laws, and published a draft policy with concessions to encourage American companies to invest.
President Obama boldly faced down critics to expand health care in the US, and before he flies to India, let’s make this the moment the US, Indian and other governments agree to put patients before profits. Add your name now:
When a giant Swiss drug company sued the Indian government over affordable medicine for cancer patients, fifty thousand Avaazers in India and Switzerland spoke out against the move, and the case was thrown out of court. Now the world’s pharmacy faces a bigger threat and it’s time to take another stand.
With hope and determination,
Alex, Bert, Laila, Ricken, Emma, Diego and the whole Avaaz team
MORE INFORMATION:
Let India make cheap drugs (Business Standard)
India-US panel: Access to medicines may be under threat (Deccan Herald)
PM's US Visit: Narendra Modi’s CEO diplomacy to soon set the cash register ringing (Economic Times)
Investment treaty tops Obama’s agenda (Business Standard)
Ebola in West Africa is a wake-up call (Al Jazeera)
Novartis loses landmark patent case in India (The Telegraph)
Avaaz.org is a 40-million-person global campaign network that works to ensure that the views and values of the world's people shape global decision-making. ("Avaaz" means "voice" or "song" in many languages.) Avaaz members live in every nation of the world; our team is spread across 18 countries on 6 continents and operates in 17 languages. Learn about some of Avaaz's biggest campaigns here, or follow us on Facebook or Twitter.
No comments:
Post a Comment
Note: only a member of this blog may post a comment.